John Charlson is an Oncology physician affiliated with Froedtert Hospital. OpenAlex indexes 125 publications with 1,510 citations (h-index 14); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
9200 W Wisconsin Ave
Neoplastic Diseases Froedtert East Clinic Bldg
Milwaukee, WI 532263522
Telephone
414-805-4612Provider last certified this registry record 1 Oct 2020.
Clinical trials
- Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
Sponsor: Medical College of Wisconsin
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Deciphera Pharmaceuticals Inc.Program year202515 payments$16,079openpaymentsdata.cms.gov ↗
- Ipsen Biopharmaceuticals, IncProgram year20253 payments
- Syndax Pharmaceuticals, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
56.1%Kinase inhibitor43.5%Imatinib Mesylate86%Tasigna14%Part D<11 patientsAromatase Inhibitor7.2%Letrozole100%Part D<11 patients+ 1 more class in this area
Nervous system
16.5%Opioid Agonist11.8%Tramadol Hcl57%Oxycodone Hcl43%Part D<11 patientsGabapentinoids4.6%Gabapentin100%Part D<11 patientsMetabolism & gastrointestinal
15.2%Serotonin-3 Receptor Antagonist15.2%Ondansetron Hcl100%Part D≥18 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- First-line ADP-A2M4CD8 T-cell Receptor T-cell Therapy plus Pembrolizumab in Head and Neck Cancers: An Additional Cohort of the Phase 1 SURPASS Trial
International Journal of Radiation Oncology*Biology*Physics
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Jonathon Truwit, MD
Froedtert Hospital
Ravi Dhingra, MD, MPH
Froedtert Hospital
Grant Sinson, MD
Froedtert Hospital
Keith Woeltje, MD
Froedtert Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”